You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
Merck
Express Scripts
Boehringer Ingelheim

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZONISAMIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Zonisamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00047567 Open-label Adjunctive Zonisamide for Bipolar Disorder Terminated Elan Pharmaceuticals Phase 4 2002-07-01 To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
NCT00055484 A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache Completed Elan Pharmaceuticals Phase 2 2002-03-01 The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache.
NCT00056576 Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Completed Eisai Inc. Phase 3 2002-02-01 The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zonisamide

Condition Name

Condition Name for Zonisamide
Intervention Trials
Epilepsy 17
Obesity 7
Healthy 6
Alcoholism 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zonisamide
Intervention Trials
Seizures 14
Epilepsy 12
Alcoholism 6
Weight Gain 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zonisamide

Trials by Country

Trials by Country for Zonisamide
Location Trials
United States 99
India 12
Australia 11
Germany 10
Italy 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zonisamide
Location Trials
Massachusetts 6
North Carolina 6
Florida 6
California 6
Connecticut 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zonisamide

Clinical Trial Phase

Clinical Trial Phase for Zonisamide
Clinical Trial Phase Trials
Phase 4 18
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zonisamide
Clinical Trial Phase Trials
Completed 38
Terminated 11
Recruiting 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zonisamide

Sponsor Name

Sponsor Name for Zonisamide
Sponsor Trials
Eisai Inc. 15
Eisai Limited 6
Eisai Korea Inc. 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zonisamide
Sponsor Trials
Other 42
Industry 42
NIH 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Moodys
McKinsey
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.